Schizophrenia Research
August 2007
F Markus Leweke, Andrea Giuffrida, Dagmar Koethe et al.
Previous studies have shown that cerebrospinal fluid (CSF) from schizophrenic patients contains significantly higher levels of the endogenous cannabinoid anandamide than does CSF from healthy volunteers. Moreover, CSF anandamide levels correlated inversely with psychotic symptoms, suggesting that anandamide release in the central nervous system (CNS) may serve as an adaptive mechanism...
Chemistry & Biodiversity
August 2007
Franjo Grotenhermen
The acute side effects caused by cannabis use are mainly related to psyche and cognition, and to circulation. Euphoria, anxiety, changes in sensory perception, impairment of memory and psychomotor performance are common effects after a dose is taken that exceeds an individually variable threshold. Cannabis consumption may increase heart rate and change blood pressure, which may have serious...
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics
July 5, 2007
Rachel F. Tyndale, Jennifer I Payne, Alexandra L Gerber et al.
A genetic variation in fatty acid amide hydrolase (FAAH), C385A (P129T), has been previously associated with risk for problem street drug use. FAAH is a mammalian enzyme that inactivates neuromodulatory-signaling lipids including the endogenous cannabinoid 1 receptor agonist anandamide. We investigated in adult Caucasians (N = 749) whether this FAAH variant altered the risk for trying, regular...
Psychological Medicine
July 1, 2007
John Macleod
A high proportion of people who have a serious mental illness also use non-prescribed psychoactive drugs. This association is perhaps most apparent, and possibly also has the greatest implications for health, in relation to tobacco use. In fact recognition of the special relationship between mental illness and smoking was recently reflected in exemption of psychiatric units from legislation to...
Schizophrenia Research
July 2007
J Boydell, K Dean, R Dutta et al.
There is considerable interest in cannabis use in psychosis. It has been suggested that the chronic psychosis associated with cannabis use, is symptomatically distinct from idiopathic schizophrenia. Several studies have reported differences in psychopathology and family history in people with schizophrenia according to whether or not they were cannabis users. We set out to test the hypotheses...
Journal of Psychiatry and Neuroscience
July 1, 2007
Philip J. Benson, Ute Leonards, Robert Lothian et al.
38 citations
OBJECTIVE: Patterns of successive saccades and fixations (scan paths) that are made while viewing images are often spatially restricted in schizophrenia, but the relation with cannabis-induced psychosis has not been examined. We used higher-order statistical methods to examine spatiotemporal characteristics of scan paths to determine whether viewing behaviour was distinguishable on a continuum....
Psychopharmacology
July 2007
Clara Touriño, Rafaël Maldonado, Olga Valverde
3, 4-Methylenedioxymethamphetamine (MDMA) and cannabis are widely abused illicit drugs that are frequently consumed in combination. Interactions between these two drugs have been reported in several pharmacological responses observed in animals, such as body temperature, anxiety, cognition, and reward. However, the interaction between MDMA and cannabis in addictive processes such as physical...
Psychological Medicine
July 1, 2007
Louisa Degenhardt, Chris Tennant, Stuart Gilmour et al.
The aim was to examine the temporal relationships over 10 months between cannabis use and symptoms of psychosis and depression in people with schizophrenia and related disorders. The design was a prospective study of 101 patients with schizophrenia and related disorders who were assessed monthly over 10 months on medication compliance, cannabis and other drug use, symptoms of depression and...
European Journal of Pharmacology
June 14, 2007
Eric J Downer, Aoife Gowran, Aine C Murphy et al.
Cannabis is the most commonly used illegal drug of abuse in Western society. Delta(9)-tetrahydrocannabinol, the psychoactive ingredient of marijuana, regulates a variety of neuronal processes including neurotransmitter release and synaptic transmission. An increasing body of evidence suggests that cannabinoids play a key role in the regulation of neuronal viability. In cortical neurons...
Journal watch
June 11, 2007
Barbara Geller
Researchers have reported a possible association between cannabis use and adolescent onset of schizophrenia, and magnetic resonance spectroscopy (MRS)